Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing-Reference-Cited by-同舟云学术

Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing

Published:2005-06-08 Issue:12 Volume:30 Page:2245-2253
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Ingman Kimmo,Hagelberg Nora,Aalto Sargo,Någren Kjell,Juhakoski Auni,Karhuvaara Sakari,Kallio Antero,Oikonen Vesa,Hietala Jarmo,Scheinin Harry

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/1300790.pdf

Reference44 articles.

1. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ et al (2004). A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24: 421–428.

2. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J et al (2003). A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142–1149.

3. Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF et al (2004). Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55: 255–262.

4. Ciccocioppo R, Martin-Fardon R, Weiss F (2002). Effect of selective blockade of mu1 or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27: 391–399.

5. Committee for Proprietary Medicinal Products (CPMP) and Internation Conference on Harmonisation (ICH) (1995). Good Clinical Practice. CPMP/ICH/135/95.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder;Substance Abuse and Rehabilitation;2024-04

2. Low-dose nalmefene pretreatment reduces etomidate-induced myoclonus: A randomized, double-blind controlled trial;Medicine;2023-09-08

3. Pharmacological Treatment of Alcohol Cravings;Brain Sciences;2023-08-15

4. Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose;Clinical Pharmacology in Drug Development;2023-07-27

5. The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (Macaca mulatta);Journal of the American Association for Laboratory Animal Science;2023-05-01